Elite Pharmaceuticals Receives FDA Approval for Generic Vyvanse
Elite Pharmaceuticals (OTCQB: ELTP) has received FDA approval for its generic version of Vyvanse (Lisdexamfetamine Dimesylate) capsules in seven different strengths ranging from 10 mg to 70 mg. The medication is designed to treat Attention Deficit Hyperactivity Disorder (ADHD). According to IQVIA data, the combined brand and generic market for this product recorded annual sales of $4.3 billion for the twelve months ending September 2024.
Elite Pharmaceuticals (OTCQB: ELTP) ha ricevuto l'
Elite Pharmaceuticals (OTCQB: ELTP) ha recibido la para su versión genérica de cápsulas de Vyvanse (Lisdexamfetamina Dimesilato) en siete diferentes dosis que van desde 10 mg hasta 70 mg. Este medicamento está diseñado para tratar el Trastorno por Déficit de Atención e Hiperactividad (ADHD). Según los datos de IQVIA, el mercado combinado de marcas y genéricos para este producto registró ventas anuales de $4.3 mil millones para los doce meses que terminaron en septiembre de 2024.
엘리트 제약(Eliit Pharmaceuticals, OTCQB: ELTP)은 FDA 승인을 받아 Vyvanse(리스데서암페타민 다이메실레이트)의 제네릭 버전 캡슐을 10mg에서 70mg의 일곱 가지 다른 용량으로 출시하였습니다. 이 약물은 주의력 결핍 과다행동 장애(ADHD) 치료를 위해 고안되었습니다. IQVIA 데이터에 따르면, 이 제품의 브랜드와 제네릭 시장은 2024년 9월을 끝으로 연간 43억 달러의 매출을 기록했습니다.
Elite Pharmaceuticals (OTCQB: ELTP) a reçu l'
Elite Pharmaceuticals (OTCQB: ELTP) hat die FDA-Zulassung für seine generische Version der Vyvanse (Lisdexamfetamin-Dimesilat) Kapseln in sieben verschiedenen Stärken von 10 mg bis 70 mg erhalten. Das Medikament ist zur Behandlung von Aufmerksamkeitsdefizit-Hyperaktivitätsstörung (ADHS) konzipiert. Laut IQVIA-Daten erzielte der kombinierte Marken- und Generika-Markt für dieses Produkt im Jahr bis September 2024 einen Gesamtumsatz von 4,3 Milliarden US-Dollar.
- FDA approval received for generic Vyvanse in seven strengths
- Entry into a large market with $4.3 billion annual sales potential
- Complete range of dosage strengths (10-70mg) approved
- Will face competition from existing brand and generic manufacturers
- Operating in OTCQB market might limit institutional investment potential
Northvale, New Jersey--(Newsfile Corp. - November 18, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for a generic version of Vyvanse® (Lisdexamfetamine Dimesylate) with strengths of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg capsules. The product is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
IQVIA reported annual sales for the twelve months ending September 2024 of
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and distributes niche generic products. Elite's product lines consist of immediate-release and controlled-release, solid oral dose products, which are marketed under the Elite Laboratories label, as well as pursuant to licenses granted to third-party pharmaceutical marketing and distribution organizations. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties, and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations
518-398-6222
Dianne@elitepharma.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/230244
FAQ
What strengths of generic Vyvanse did Elite Pharmaceuticals (ELTP) receive FDA approval for?
What is the market size for Vyvanse according to Elite Pharmaceuticals' (ELTP) announcement?
What medical condition will Elite Pharmaceuticals' (ELTP) generic Vyvanse treat?
